Tirzepatide

A secret shopper study revealed that telehealth sites prescribing GLP-1 medications for weight loss often operate with minimal clinical oversight, enabling fast and easy access to drugs like semaglutide and tirzepatide. The study, conducted by a Yale researcher and published in the Journal of the American Medical Association, highlights concerns about virtual care practices and the market for non-FDA-approved compounded versions due to shortages.

Medicare will start covering weight-loss drugs via a temporary pilot program on July 1, allowing millions of enrollees access to medications like Wegovy and Zepbound at significantly reduced costs under a deal with Eli Lilly and Novo Nordisk. The program aims to address obesity as a treatable disease, offering seniors like Mary and Jeff Abrahamson affordable options that improve health outcomes.

Peptides are widely promoted in health and beauty for benefits like weight loss and tissue repair, but many sold as 'research only' lack FDA approval. The FDA is easing access to peptides despite warnings about undermining drug approval, while experts note that only rigorously studied, FDA-approved peptides (like Tirzepatide and Semaglutide) have strong scientific backing.

Medicare will cover weight-loss drugs for the first time starting July 1 through a temporary pilot program called Medicare GLP-1 Bridge. The program aims to reduce costs for medications like Zepbound and Wegovy, which are expensive without insurance, providing financial relief for seniors like Mary and Jeff Abrahamson who previously relied on compounded versions of tirzepatide.

2-year results from the SUPPRESS-EARLY trial indicate that early use of tirzepatide (Mounjaro, Zepbound) in type 2 diabetes management significantly improves outcomes. The findings were presented at the American Diabetes Association annual meeting.

Jenny Mollen described severe side effects, including 'blood everywhere,' from microdosing Tirzepatide, a GLP-1 drug typically used for diabetes, while taking a cocktail of peptides.

Jenny Mollen reported severe side effects, including 'blood everywhere,' from microdosing Tirzepatide, a GLP-1 weight loss drug, while taking a cocktail of peptides.

Research indicates the GLP-1 drug tirzepatide may enhance brown fat activity, which could increase calorie burning in the body. This effect occurs alongside appetite suppression, potentially offering additional weight management benefits.

A study finds combining apitegromab with tirzepatide may help preserve lean muscle while supporting weight loss in people with obesity.

GLP-1 weight-loss drugs are reducing U.S. consumption of carbon-intensive foods like red meat and sugary drinks, leading to significant declines in food-system emissions. Clinical data shows users cut calorie intake by 21% and grocery spending by 5–6%, with Wall Street projecting billions in lost food sales by 2030. The shift aligns with federal dietary guidelines and could surpass climate policy in reducing emissions.

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated their effectiveness in a head-to-head analysis.

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza).

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza) to determine their effectiveness.

Serena Williams, a paid spokesperson for telehealth company Ro, used GLP-1 weight-loss drugs to lose 34 pounds and claims the medication improved her training and tennis performance. The article explores whether GLP-1s should be classified as performance-enhancing drugs, noting the World Anti-Doping Agency is monitoring their use, though current rules allow athletes to take them.

A new study suggests that adults taking GLP-1 medications like Ozempic or Wegovy for weight loss are significantly reducing their physical activity, with decreases in daily steps and moderate-to-vigorous exercise. Researchers emphasize that exercise remains essential for preserving strength and long-term health when using these drugs, despite the observed decline in activity.

A new study suggests GLP-1 weight-loss drugs like semaglutide and tirzepatide may significantly slow the progression of obesity-related cancers such as lung, breast, colorectal, and liver cancers. Conducted by Cleveland Clinic and to be presented at the 2026 ASCO Annual Meeting, the retrospective analysis found GLP-1 users had up to 50% lower risk of cancer advancing to stage 4 compared to patients taking DPP-4 inhibitors.

The peptide market is experiencing rapid growth as GLP-1 weight-loss medications gain popularity, with largely unregulated peptides being sold through compounding pharmacies and unverified vendors. The FDA is evaluating whether to loosen regulations on several peptides, while compounding pharmacies have expanded to meet demand and offer dosing flexibility that commercial products cannot provide.

A 30p supplement can help with weight loss and reduce diabetes risk. Experts discuss why people trying to stop taking Mounjaro must continue and how it can prevent a common side effect. The supplement has shown promising results in managing weight and diabetes.

Rapid weight loss is causing a new side effect called 'Ozempic arms', which leaves people with aged and sagging skin, even in 35-year-olds. This condition is a result of significant weight loss. The term 'Ozempic arms' refers to the loose skin that remains after weight loss.

GLP-1 drugs like semaglutide and tirzepatide, popular for weight loss and diabetes management, offer cardiovascular and kidney benefits but require careful use. Dr. Meena T. Malhotra warns against common mistakes, emphasizing lifestyle changes, medical oversight, and avoiding online purchases without proper evaluation.

A study in Nature found genetic variations in the GLP1R and GIPR genes influence the effectiveness and side effects of GLP-1 receptor agonists like semaglutide and tirzepatide. Patients with specific gene variants experienced modest weight loss boosts and increased nausea risks, highlighting potential for personalized treatment approaches.

A study analyzing Reddit posts from 67,000 users revealed previously undocumented side effects of GLP-1 medications like semaglutide and tirzepatide, including menstrual irregularities, psychiatric symptoms, and fatigue. Researchers from the University of Pennsylvania highlight discrepancies between clinical trial data and real-world user experiences.